Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

47.57
-2.4900-4.97%
Post-market: 47.670.1000+0.21%19:59 EDT
Volume:18.52M
Turnover:890.28M
Market Cap:96.81B
PE:17.81
High:49.80
Open:49.74
Low:47.40
Close:50.06
Loading ...

Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires?

Insider Monkey
·
15 Apr

BRIEF-Bristol Myers Squibb Provides Update On Phase 3 ODYSSEY-HCM Trial

Reuters
·
15 Apr

BUZZ-Bristol Myers falls as heart disease drug fails in late-stage trial

Reuters
·
15 Apr

Bristol-Myers' Camzyos Phase 3 Trial Misses Dual Primary Endpoints

MT Newswires Live
·
15 Apr

CORRECTED-UPDATE 2-Bristol Myers' heart disease drug fails to meet main goals in late-stage study (April 14)

Reuters
·
15 Apr

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
15 Apr

Bristol Myers says Phase 3 ODYSSEY-HCM Camzyos trial did not meet endpoints

TIPRANKS
·
15 Apr

Bristol-Myers Squibb Co - No New Safety Signals Observed in Odyssey-HCM Trial

THOMSON REUTERS
·
15 Apr

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

Business Wire
·
15 Apr

Nu, HPE, Merck, BMY, OXY: Trending by Analysts

TIPRANKS
·
12 Apr

Bristol-Myers Squibb Gets FDA Approval for Opdivo-Yervoy Combo in Liver Cancer Treatment

MT Newswires Live
·
12 Apr

FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas

Dow Jones
·
12 Apr

Bristol Myers says FDA approves Opdivo plus Yervoy as first-line HCC treatment

TIPRANKS
·
12 Apr

Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says

MT Newswires Live
·
12 Apr

Pharma Tariffs Are Coming. Investors Underestimate the Risk. -- Barrons.com

Dow Jones
·
12 Apr

BRIEF-FDA Approves Nivolumab With Ipilimumab For Unresectable Or Metastatic Hepatocellular Carcinoma

Reuters
·
12 Apr

Bristol-Myers Squibb Is Maintained at Neutral by UBS

Dow Jones
·
11 Apr

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

THOMSON REUTERS
·
11 Apr

UBS Cuts Price Target on Bristol-Myers Squibb to $54 From $60, Keeps Neutral Rating

MT Newswires Live
·
11 Apr

Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today

Zacks
·
10 Apr